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Introduction: Research has demonstrated that functional outcome in psychosis is
predicted by factors such as neurocognition, functional capacity, symptoms and,
more recently, metacognition. Metacognitive ability has been demonstrated to mediate
between neurocognition and functional outcome in First Episode Psychosis (FEP).
Whether metacognition also predicts longer-term recovery in first episode psychosis
is unknown. This study assessed whether neurocognition, functional capacity and
metacognitive ability in FEP predicted functional outcome three years later.
Methods: Eighty individuals with First Episode Psychosis were re-contacted after an
average 3 years (range: 26–45 month follow-up) from baseline. Twenty-six participants
(33%) completed completed measures of neurocognition, metacognition, functional
capacity, functional outcome (hours spent in structured activity per week) and
psychopathology at baseline and at follow-up.
Results: Individual regression analyses demonstrated neurocognition, functional
capacity, and metacognitive ability at baseline significantly predicted functional outcome
at three years. However, when baseline functional outcome was controlled, only
metacognitive ability was a significant predictor of change in functional outcome from
baseline to follow-up, p < 0.001. This model explained 72% (adjusted r² = 0.69) of
the variance in functional outcome at follow-up. Negative symptoms did not change
the model.
Discussion: This study demonstrated that better metacognitive ability significantly
predicted improvement in functioning in FEP across a 3-year period. This highlights the
potential value of clinical interventions that focus on improving metacognitive ability at
first point of illness to maximize recovery.
Keywords: first episode psychosis, metacognition, functioning, longitudinal, cognition, negative symptoms,
functional capacity
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INTRODUCTION
Clinical recovery can be considered improvement in
symptomatology and social/occupational functioning (1, 2).
Although clinical recovery after an experience of psychosis
was previously considered poor (3), recent research has
demonstrated that around 50% of individuals with psychosis
had favorable outcomes after long follow-up periods (4–6) and
this has also been demonstrated with First Episode Psychosis
(FEP) (7, 8). A 10-year follow-up study showed 77% of
participants showed at least one period of recovery (defined
as sustained symptom remission for at least two years) with
46% symptom-free for at least two years (9). However, for (10)
and Robinson et al. (8) only 6.6% and 14% (respectively) met
the criteria for full recovery after 1 and 5 year(s) (respectively),
suggesting clinical recovery during early stages of illness
may be slow. There is clear interest in understanding factors
that influence clinical recovery in psychosis, particularly
FEP where recovery may be more likely (4, 9). Birchwood
et al. (11) named this the critical-period, highlighting the
importance of early and targeted interventions to prevent further
decline (12–14).
Social and occupational functioning, an aspect of clinical
recovery, is a measurable aspect of an individual’s specific
activities of daily living. Hodgekins et al. (15) suggested assessing
functioning using time spent in structured activity per week
(4, 16), including employment, education, sports, and leisure.
Research has demonstrated that time spent in structured activity
is on average 63.5 h in the healthy population, 25.2 h in FEP
sample (17), and 19.7 h in a psychosis sample with delayed
recovery (15). Importantly, engaging in more hours of activity,
e.g., paid work, has been associated with reduced symptoms and
improved overall functioning in interventions studies (18, 19).
Research has demonstrated difficulties in functioning across
the course of recovery in psychosis and, therefore, the importance
of focusing on understanding and improving poor functional
outcome. Despite advances in psychological interventions for
psychosis, outcome remains poor. There is value in the
identification of those with psychosis who are at risk of poor
functioning across time, to target interventions to reduce this
disability. There are four selected lines of evidence which
will be discussed here to suggest factors which predict poor
functioning: (i) neurocognition, (ii) functional capacity, (iii)
negative symptoms and (iv) metacognition.
Research assessing functional outcome within individuals
with psychosis has focused on the influence of neurocognitive
difficulties (20–22). The relationship between neurocognition
and functional outcome has been demonstrated cross-sectionally
(23, 24) and longitudinally in schizophrenia (8), FEP (25,
26) and Ultra-High Risk groups (27). However, studies have
demonstrated that predicting those who would have poor
outcome with neurocognitive variables is substantially more
straight-forward than predicting those who would recover (28,
29). This suggests a more complex relationship with additional
factors to be explored.
Functional capacity has also been shown to predict real-
world functional outcome within schizophrenia (30, 31) and FEP
(32). Neurocognitive ability has been shown to be associated
with functional capacity (33–35) and functional capacity has
been shown to mediate between neurocognition and functional
outcome in schizophrenia (36) and FEP (32). A longitudinal
study demonstrated functional capacity predicted real-world
functioning in psychosis for those with positive, but not for
those with negative symptoms (37). The authors suggested that
negative symptoms are distinct and can impact functioning, more
so than functional capacity.
Models have highlighted that negative symptoms predict
functional outcome in psychosis (38, 39). Specifically, negative
community symptoms (e.g., amotivation or social withdrawal),
when combined with cognitive deficits, have the largest
impact on functioning in schizophrenia (40). Longitudinal
studies have demonstrated that lower levels of negative
symptoms predicted better outcomes in FEP in a large
study of 304 participants (41). When assessing positive
and negative symptom trajectories, poorer negative symptom
trajectories were associated with poorer social functioning,
disorganized symptoms, and schizophrenia diagnosis, compared
to positive symptom trajectories which were associated with
DUP and substance use (42). However, Alvarez-Jimenez et al.
(43) demonstrated that whilst symptom remission predicted
functional recovery, negative symptoms had little predictive
value for long-term functioning. Studies have noted an overlap
in the variance in outcome explained by cognition and negative
symptoms (25, 44) and, when taking into consideration the role
of cognition, symptoms are shown not to predict functioning
cross-sectionally (45) and later longitudinally (46). These studies
highlight that functional outcome is the product of a complex
array of abilities and symptoms.
Following this research, models in psychosis suggest that
neurocognition, functional capacity, and negative symptoms
influence functional outcome (33, 47, 48). The path between
neurocognition and functioning has been shown to be mediated
by functional capacity and cognitive processes (36, 47–49),
including defeatist performance beliefs and self-stigma (50) and,
most recently, metacognition (32).
Metacognition is considered “thinking about thinking” (51) or
the way one thinks about one’s experience (52). Metacognition
involves forming an integrated representation of oneself, others,
and the world and using these representations to implement
an effective action strategy to perform or accomplish a task
(53). Nelson and Narens (54) outlined a metacognitive model
suggesting an object-level which (cognitive processes) and a
meta-level (an abstract view of the object-level) which are
connected by metacognitive processes. Metacognition may be
fractionated and three levels of metacognition have been
proposed. Firstly, metacognitive ability: capacity to think about
one’s own cognitions, emotions and behavior, and to use
this reflection to respond to challenges (55, 56). Secondly,
metacognitive experience: an online appraisal of one’s experience,
and thirdly, metacognitive sensitivity: a sub-conscious awareness
of performance during a task. The first level, metacognitive
ability, measured using Metacognitive Assessment Scale (MAS)
(57) or Metacognitive Assessment Interview (MAI) (58), is
shown to predict real-life functioning in schizophrenia (59–61).
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In particular, metacognitive ability is show to be a mediator
between neurocognition and functioning in schizophrenia (62)
and FEP (32, 63). Metacognitive ability is shown to have a large,
key role in functioning in psychosis, although this relationship is
also influenced by neurocognition and functional skills.
Whether the relationship between metacognition and
functional outcome persists across time is unknown.
Intervention studies focusing on improving metacognition
have demonstrated an increase in real-world functioning
(64–67). Longitudinal studies demonstrated that metacognitive
ability, particularly one’s ability to use representations of self
or other to implement effective strategies, predicted social
functioning across a 5-month period in schizophrenia (68)
and McLeod et al. (69) demonstrated that metacognitive
ability predicted negative symptoms at 12 months in FEP,
independent of known factors, e.g., gender, DUP and premorbid
academic/social adjustment. However, no study has yet assessed
the role of metacognitive ability on functioning over a longer
follow-up period; particularly within FEP.
It may be suggested that metacognitive ability enables the use
of appropriate skills and abilities to perform a task or challenge.
For example, an individual may have poor neurocognitive ability,
but if they have appropriate metacognitive ability then they
may be able to use their available resources and strategies in
order to overcome challenges in the environment. Successful
outcome, following the utilization of metacognitive ability,
may predict engagement in more activities over that predicted
by neurocognition, functional capacity skills and negative
symptoms. Lysaker et al. (70) demonstrated that those with
schizophrenia and high metacognitive ability display better work
performance across 6-months, as those with high metacognitive
ability were able to see their conclusions as fallible and were able
to learn and adapt to the changing demands of work. Therefore,
metacognitive ability may be the key predictor of a change in
functional outcome across time.
From this, it is hypothesized that functional outcome in FEP
at 3-year follow-up will be predicted by metacognitive ability
at baseline, independent of neurocognition, negative symptoms,
and functional capacity. It is also hypothesized that a change
in functional outcome will be predicted by metacognitive ability




Ethical and Health Research Authority approval was obtained
through Camberwell St. Giles Research Ethics Committee
(reference number: 17/LO/0055). All participants provided
written informed consent at first entry to the study. Participants
who gave consent to be re-contacted were contacted after the 3-
year period and provided written informed consent at follow-up.
Design
This was a longitudinal follow-up study exploring the
contribution of metacognitive ability to functional outcome at
3-year follow-up with individuals with First Episode Psychosis.
Full details of the study design and ethical approval is provided
in the protocol (71). Details of the baseline study are provided in
an earlier publication (32).
Participants
Participants with First Episode Psychosis were recruited, via
a convenience sample, from outpatient Early Intervention in
Psychosis services in Sussex Partnership NHS Foundation Trust
Sussex, UK. All participants had been within Early Intervention
Services for at least 3 months before entry into the study. All
participants received a diagnosis of First Episode Psychosis (F29)
by a psychiatrist at entry to the study. Participants with a primary




This was assessed using the Metacognitive Assessment Interview
(MAI) (58), which requires the participant to reflect on a recent
difficult interpersonal experience and to answer a series of
questions reflecting on this experience. The measure assesses the
individual’s ability for (i) monitoring, identification of feelings
and thoughts, (ii) differentiation, distinguishing between dreams,
beliefs or assumptions, (iii) integration, reflection on different
mental states and rules governing them, and (iv) decentralization,
describing the mental state of the other which is independent
of their own view. These four subscales are scored between
0 and 5, depending on spontaneity, use of aids/prompts and
the sophistication of the answer. The scores for the sub-
domains are averaged to provide one multidimensional score.
This measure has demonstrated good inter-rater reliability and
internal consistency (α = 0.91 for total metacognition), and
construct reliability showing correlations amongst theMAI scales
(r = 0.62–0.9) (58).
Function
Functional outcome
Time-Use Survey (TUS) (72) is a structured interview [inter-
rater reliability 0.99; (15)] during which participants are asked
questions regarding the number of hours spent engaged in
specific structured activities for the preceding month (D 15),
including hours spent in paid work, voluntary work, educational
activity, childcare, sports, leisure, and housework activities. A
weekly average was calculated for each activity. Two total scores
can be produced: (i) constructive economic activity (CEA)
including the total hours per week in employment, education,
voluntary work, childcare and housework and chores and (ii)
structured activity (SA) including the total hours per week
in constructive economic activity, leisure activities, and sports
activities. Within this study, we used structured activity as the
total score. This measure is able to capture differences across
clinical groups (15, 73).
Functional capacity
The UCSD Performance-Based Skills Assessment (74) provides
a total score for real-life performance skills based on role-play
tasks. This measure is divided into five sections: (i) finance, e.g.,
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countingmoney, (ii) communication, e.g., re-arranging amedical
appointment, (iii) comprehension/planning, e.g., planning a visit
to a theme park, (iv) transport, e.g., reading a bus timetable, and
(v) household, e.g., creating a shopping list from a recipe. During
each role-play the individual is given points by the researcher
from the manual guidelines. These raw scores are totaled for
each domain, converted into 0–20 scale then multiplied by 2 and
summed to provide a total out of 100. This measure demonstrates
high internal consistency (α =0.88), good validity with other
scales (Direct Assessment of Functional Status scale, r = 0.86)
and good test-retest reliability (r = 0.91) (75–77).
Neurocognitive Ability
Participants completed a battery of neurocognitive measures,
including Verbal and working memory [Logical Memory
and Letter-Number Sequencing subscales from the Wechsler
Memory Scale (WMS-III)], executive function (Trail-Making
Task and Verbal Fluency), Verbal and Performance IQ
(Vocabulary and Matrix reasoning tasks). All scores were
converted into Z scores using age-scaled population means and
standard deviations (78, 78–80). A neurocognitive composite
score at baseline was produced from themeasures outlined above.
IQ was assessed at follow-up using Vocabulary task and Matrix
reasoning task (78).
Symptoms
Positive and Negative Syndrome Scale (81) was used as
this is the most widely used standardized instrument for
assessing symptom severity in schizophrenia (82). This measure
provided three separate scores for positive, negative and general
psychopathology symptoms.
PLANNED ANALYSIS
G power estimation was used for a power calculation based on
a power of 0.80, effect size of 0.31 (32) and alpha of 0.05. This
suggested a total of 44 participants were required when including
4 predictors.
Hypothesis Testing
Descriptive statistics were produced for neurocognitive ability,
metacognitive ability, functional capacity, functional outcome,
and symptoms, and scores were compared from baseline to
3-year follow-up using t-tests. At baseline, a large battery of
neurocognitivemeasures was collected. At follow-up, onlymatrix
reasoning and vocab measures (as a two-part IQ score) were
collected. Therefore, the difference tests (comparing baseline and
follow-up) only assessed differences in these measures.
For the main analyses, predictors of functional outcome
at three follow-up were explored (predictors included:
neurocognition, negative symptoms, functional capacity,
and metacognition). In light of the small sample size, and
in order to reduce the number of predictors in the model,
a series of single regression analyses were used to assess the
predictive value of each variable at baseline on functional
outcome at 3-year follow-up. After this, a stepwise regression
was conducted using only the significant predictors as covariates
and metacognitive ability was added to the model in block 2, to
assess the independent contribution of metacognitive ability.
Next, the predictive value of variables on change in functional
outcome from baseline to follow-up was assessed. The change
was assessed by using baseline functional outcome as a covariate,
adjusting the mean for the baseline levels, to explore differences
in functional outcome at follow-up. Then, significant predictors
were used as covariates and metacognitive ability added to the
model in block 3. It is important to note that the Time-Use
survey has been demonstrated to be sensitive to change over
time in clinical trials [see (83, 84)]. Due to the sample size and
to minimize the number of predictors within a single model,
the independent role of neurocognition, negative symptoms,
and functional capacity were used as covariates within three
parallel analyses.
RESULTS
Data and Assumption Checking
Missing data was considered as “Missing Completely At
Random” (MAR), as missing data was not associated with
data within the study. All predictor and outcome data were
checked for skewness, kurtosis, and outliers. MAI total at
baseline displayed a multimodal distribution. There were
no significant differences on cognition, functional capacity,
functional outcome, symptoms, and metacognitive ability for
those who participated in follow-up and those who did not.
Sample Characteristics
The first recruitment phase took place during 2013–2015. The
follow-up recruitment phase took place within 2017, after 3 years
(average 36-month; range 26–45-month follow-up). The baseline
sample included 80 participants with FEP (49 men, 31 female)
with a mean age of 26.08 years (SD= 5.53). Seventy-seven people
provided consent to re-contact. Twenty-six participants from the
baseline study took part in the follow-up assessment (see Figure 1
for flowchart of participation). The mean age at follow-up was
28.93 (SD = 5.55, range 22–43) with 23 males and 8 females (see
Table 1). See Supplement A for distribution of months between
baseline and 3 years for the sample followed-up.
Descriptive Statistics
See Table 1 for descriptive statistics. A number of variables
increased over the two timepoints: vocabulary score (p = 0.04),
functional capacity (UPSA) (p < 0.001), functional outcome
(time-use structured activity) (p = 0.01) and metacognitive
ability (MAI) (p = 0.03). Negative symptoms decreased
(p= 0.01) (see Table 1 for descriptive statistics).
Associations Between Predictor Variables
See Table 2 for correlation matrix for neurocognition,
metacognitive ability, symptoms, functional capacity and
functional outcome at baseline and follow-up. Age at baseline
was significantly associated with functional outcome at follow-up
(r = 0.4, p = 0.027) and included as a covariate in subsequent
analyses. For neurocognition, a Confirmatory Factor Analysis
was conducted on the z scores of the cognitive variables at
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FIGURE 1 | Flowchart for re-recruiting individuals from baseline study into
longitudinal study1.
baseline and converted into a neurocognitive factor score for
each participant.
Hypothesis 1
In order to test predictors (neurocognition, functional capacity,
negative symptoms and metacognition) of functional outcome at
3-year follow-up, individual regression analyses were conducted.
Neurocognitive ability at baseline did not significantly predict
functioning at 3 years, p = 0.24. Functional capacity, F(2, 25)
6.66, p = 0.01, negative symptoms, F(2, 23) 5.69, p = 0.01, and
metacognitive ability, F(2, 24) 27.97, p < 0.001, were significant
predictors of functioning at 3 years. Including negative symptoms
as a covariate in the above analyses did not substantially change
the significance levels for neurocognition and metacognitive
ability (p = 0.44 and p < 0.001, respectively). However,
when controlling for negative symptoms, functional capacity
at baseline was no longer a significant predictor of functional
outcome at follow-up (1R2 = 0.07 p= 0.13).
111 people were untraceable: 1 participant was not on the records system and 10
people provided contact details which were now out-of-date and were no longer
connected to services.
Next, in order to test whether metacognition predicted
functional outcome at follow-up independent of other known
factors, significant predictors (functional capacity and negative
symptoms) were included in the first block of the stepwise
regression then the independent contribution of metacognitive
ability (MAI) to functioning at three-year follow-up was assessed
(see Table 3). This model explained 77.1% (adjusted r² = 0.72)
of the variance in functional outcome at follow-up (R = 0.77,
F(4, 23) 16.01, p < 0.001). MAI significantly improved the model
(1R2 = 0.35, p < 0.001) explaining 34.6% of the 77% (adjusted
r²= 0.72) total variance explained.
Hypothesis 2
In order to assess predictors (neurocognition, functional
capacity, negative symptoms, and metacognition) of a change
in functional outcome from baseline to 3-year follow-up,
individual regression analyses were conducted, controlling for
baseline functional outcome. Neither neurocognition (p = 0.22),
functional capacity (p= 0.57) nor negative symptoms (p= 0.35)
predicted change in functional outcome. Metacognitive ability
(MAI) was a significant predictor of change in functional
outcome at follow-up, when including baseline functional
outcome as a covariate. This model explained 72% (adjusted
r² = 0.69) of the variance in functional outcome at follow-up
(R=0.72, F(3, 25) 19.22, p < 0.001). MAI significantly improved
the model (1R= 0.12, p = 0.01), explaining 12% of the 72%
total variance explained (see Table 4). VIF values were inspected
to check multicollinearity and the score was acceptable (85,
86). Even when separately controlling for negative symptoms,
neurocognition, and functional capacity in parallel analyses,
metacognitive ability was still a significant predictor of change in
functional outcome from baseline to follow-up [controlling for
neurocognition (p= 0.005), negative symptoms (p= 0.006), and
functional capacity (p= 0.001)].
For those participants who were followed-up, metacognitive
ability (MAI) at baseline demonstrated a bivariate distribution
(Supplement B). We, therefore, compared those with FEP and
either high or low metacognitive ability graphically, with other
previous samples. Specifically, we divided participants into two
groups: high MAI at baseline (N = 14) or low MAI at baseline
(N = 12), using mean split, to assess the changes in time-
use scores between the groups. Individuals in the high MAI
group demonstrated a difference in hours spent in structured
activity between baseline (M = 50.32, SD = 23.98) and follow-
up (M = 58.13, SD = 19.29) (p = 0.05), but for the low MAI
group there was no significant difference (p= 0.17) in structured
activity between baseline (M = 13.17, SD = 7.7) and follow-up
(M = 15.53, SD= 7.63) (see Figure 2).
DISCUSSION
This was the first study to assess the role of metacognitive
ability on functional outcome longitudinally across three-years
in First Episode Psychosis. This study was able to demonstrate
that functional outcome improved over time and, whilst negative
symptoms and functional capacity predicted functioning at 3
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TABLE 1 | Sample characteristics and descriptive and change statistics for neurocognitive measures, functional capacity, functional outcome, metacognitive ability,
and symptoms.
Baseline (N = 26) Three-year follow-up (N = 26) Differences test (baseline to follow-up)
Age, yrs. (SD) 25.9 (5.94, range 19–39) 29.32 (6.18, range 22–43)
Gender (M/F) 19/7 19/7
Education (years) 13.67 (2.09)
13.67 (range 11–16)
13.64 (range 11–16)a
Medication (Y/N) 22/4 18/8
Matrix reasoning (t-score)b 51.6 (8.71) (range 24–68) 54.17 (5.52) (range 41–66) t(23)−1.96, p = 0.06
Vocabulary (t-score) 49.62 (12.79) (range 35–70) 54.23 (12.57) (range 21–70) t(24)−2.2, p = 0.04*
UPSA total (0–100) 74.66 (13.45) (range 42.94–93.18) 83.09 (9.18) (range 57.96–96.6) t(24)−4.35, p < 0.001***
Time Use CEA (hours in activity per week) 22.07 (19.95) (range 0–70.62) 31.66 (22.87) (range 0.81–88.96) t(25)−2.66, p = 0.01*
Time Use SA (hours in activity per week) 29.82 (22.3) (3–74.80) 39.31 (24.81) (range 6.06–96.46) t(25)-2.47, p = 0.02*
MAI total (0-5) 2.77 (1.32) (range 0.88–4.56) 3.27 (0.87) (range 1.63-4.44) t(25)-2.28, p = 0.03*
Symptoms (positive) (7-49) 11.44 (3.63) (range 7–19) 11.87 (4.7) (range 7–23) t(23) −1.23, p = 0.23
Symptoms (negative) (7-49) 13.40 (4.06) (range 7–22) 10.87 (3.89) (range 7–26) t(23)2.92, p = 0.01**
Symptoms (general) (16-112) 28.68 (6.9) (range 17–43) 26.0 (5.68) (range 18–38) t(23) 1.5, p = 0.15
Symptoms (total) (30-201) 53.52 (12.36) (range 32–79) 48.73 (12.84) (range 34–85) t(23) 1.2, p = 0.24
Bold: Differences were significant at p < 0.05. *p < 0.05, **p < 0.01, ***p< 0.001. UPSA, UCSD Performance-Based Skills Assessment; CEA, Constructive Economic Activity; SA,
Structured Activity; MAI, Metacognitive Assessment Interview (total).
aData for follow-up was captured as categories (e.g., GCSE, A-level, Degree, higher degree) which was subsequently converted into years of education to match the baseline groupa.
bAt baseline, a large battery of neurocognitive measures was collected. At follow-up, only collected matrix reasoning and vocab measures (as a two-part IQ score) was collected.
Therefore, the t-tests in this table only assesses differences in these measures.
TABLE 2 | Correlation matrix for neurocognition, metacognition, symptoms, functional capacity, and functional outcome at baseline and follow-up.
1 2 3 4 5 6 7 8 9 10 11 12 13
Neurocognitive factor (baseline) 1 –
Metacognition (baseline) 2 0.61** –
Positive symptoms (baseline) 3 −0.22 −0.15 –
Negative symptoms (baseline) 4 0.43** −0.64** 0.17 –
General psychopathology symptoms (baseline) 5 −0.22 −0.39** 0.59** 0.52** –
UPSA (baseline) 6 0.48** 0.53** −0.09 −0.44** −0.15 –
Time–use (baseline )7 0.48** 0.84** −0.1 −0.49** −0.27* 0.39** –
Metacognition (follow–up) 8 0.66** 0.64** −0.33 −0.56** −0.33 0.66* 0.4* –
Positive symptoms (follow–up) 9 −0.32 −0.36 −0.39 0.28 0.17 −0.31 −0.29 −0.59** –
Negative symptoms (follow–up) 10 −0.54** −0.46* 0.3 0.51* 0.13 −0.46* −0.34 −0.55** 0.71** –
General psychopathology symptoms (follow–up) 11−0.28 −0.44* 0.38 0.23 0.26 −0.34 −0.47* −0.31 0.75** 0.67** –
UPSA (follow–up) 12 0.71** 0.63** −0.29 −0.42* −0.31 0.74** 0.3 0.49** −0.29 −0.48* −0.24 –
Time–use (follow–up) 13 0.29 0.82** 0.02 −0.41* −0.23 0.54** 0.74** 0.42* −0.37* −0.46* 0.47** 0.5** –
*p < 0.05, **p < 0.01.
years, the improvement in functioning was largely predicted by
metacognitive ability and baseline functioning.
Within this study, individuals with FEP significantly improved
in neuro cognitive ability (vocabulary), real-life functional
capacity skills, metacognitive ability and negative symptoms
over 3 years. At baseline, individuals within this sample were
demonstrating typical mean activity levels for an FEP sample
(29.82 h per week) [see (15)], but there was an improvement of
9 hours in structured activity at three-year follow-up, resulting
in a time-use score similar to an ARMS group [see (15)]. There
was an increase in functional capacity, in that individuals at
follow-up were similar to those typically residing independently
and employed (76). There was a significant improvement in
verbal neuro cognitive ability (vocabulary). Studies in the general
population suggest vocabulary is stable over time (87), including
studies within schizophrenia (88, 89). The increase in verbal
cognition may be the consequence of an initial drop in neuro
cognitive ability, particularly verbal IQ (90, 91), which then
recovered throughout the follow-up period.
Findings demonstrated that functional capacity and negative
symptoms, but not neurocognition, at baseline predicted
functional outcome at 3 years after FEP, supporting and
furthering research (33, 37, 41, 42). Neurocognition did not
directly predict functional outcome at 3-years. However, previous
studies have suggested that neurocognitive factors only predict
a small amount of variance in real-world functioning (36)
Frontiers in Psychiatry | www.frontiersin.org 6 April 2019 | Volume 10 | Article 182
Wright et al. Exploring Metacognition in Psychosis
TABLE 3 | Full regression model for predictive value of metacognitive ability on
functional outcome at three years, whilst controlling for age, UPSA, and PANSS
negative symptoms.
B SE B β p-value CI
MODEL 2
Constant 7.09 35.2
UPSA −0.58 0.44 −0.33 0.2 −1.5, 0.33
PANSS negative −0.14 1.15 −0.02 0.91 −2.54, 2.27
Age 0.89 0.54 0.22 0.12 −0.25, 2.03
MAI (total) 18.99 3.54 1.05 <0.001*** 11.57, 26.4
***p < 0.001.
UPSA, UCSD Performance-Based Skills Assessment; PANSS, Positive And Negative
Syndrome Scale; MAI, Metacognitive Assessment Interview (total).
TABLE 4 | Full regression model for predictive value of metacognitive ability on
change in functional outcome from baseline to follow-up, whilst controlling for
baseline functional outcome, and age.
B SE B β p-value CI
MODEL 2
Constant −25.69 14.12
Age 0.93 0.53 0.21 0.1 −0.18, 2.04
Time use baseline 0.21 0.24 0.18 0.38a −0.28, 0.70
Metacognitive ability (MAI)b 12.21 4.00 0.61 0.01** 3.88, 20.53
**p < 0.01.
aWhen include age as a covariate, functional outcome at baseline was no longer
significant.
bMAI, Metacognitive Assessment Interview (total).
and other factors have a more substantial role. Alternatively,
neurocognitionmay have an indirect role, via functional capacity,
as the present study demonstrated an association between
neurocognition and functional capacity, or neurocognition and
negative symptoms as Fervaha et al. (92) demonstrated, using
a factor analysis, that negative symptoms may be divided into
amotivation and diminished expression and it is the former
factor, combined with cognitive deficits, that has the largest
impact on functioning in schizophrenia.
Importantly, this study demonstrated that functional outcome
at three-years was predicted by metacognitive ability, supporting
previous cross-sectional studies (32, 62, 93).Metacognitive ability
was also the only significant predictor of improvement in
functioning, accounting for a significant change in functioning
over time. Therefore, whilst negative symptoms and functional
capacity skills predicted functioning at 3-years, this study
highlights that those with higher metacognitive ability at baseline
may be better able to make use of strategies and resources (e.g.,
from the early intervention service) to improve their functioning
over time, compared to those with lower metacognitive ability
who may need more guidance in order to utilize the services
available to them.
In further exploring metacognitive ability at baseline, it
was evident that individuals who displayed low metacognitive
ability at baseline demonstrated limited change in functioning
at 3-year follow-up, compared to individuals who displayed
adequate metacognitive ability. This may suggest that those with
better metacognition were better able to reflect on their thoughts,
strengths, as well as perspectives of others, and use appropriate
strategies to implement in the real world. Metacognitive ability
was a longitudinal predictor of functional outcome, independent
of IQ. Whilst the sample size in the group is small, this supports
the main hypothesis that early metacognitive factors influence
change in functioning.
A large amount of the variance in time-use at follow-
up was predicted by baseline time-use and age. Therefore,
individuals with better initial functioning are more likely to
show an improvement later on, compared to those who had
lower functioning who showed no change in already poor
functioning. This finding may suggest that those with poor
functioning at baseline have poorer metacognitive abilities. The
poor metacognitive ability then may predict lower prospective
functioning or strategies to improve their poor functioning or are
less motivated, due to poor cognitive and metacognitive ability
(94, 95), both of which lead to less change or improvement in
functioning over time. This study defined functional outcome
as a measurable aspect of an individual’s specific activities of
daily living and social and occupational functioning. The Time-
Use Survey is a relatively objective and specific measure of
functioning, sensitive to change over time [see (16, 83, 84) and
across stages of psychosis see (15)]. Future studies could look at
changes in subjective recovery outcomes [see (96)], following the
service usermovement (97), to identify longitudinal relationships
with metacognition. These findings highlight the importance
of the Early Interventions services to focus on improving
functioning and encouraging early help-seeking to prevent low
levels of functioning initially.
These findings can be taken forward in two ways: (i) poor
metacognitive ability may be a marker for poor outcome in
psychosis later on, and (ii) metacognitive ability may be a
key ability for interventions to target in early psychosis to
improve subsequent functioning. If metacognitive ability does
play a role, metacognitive interventions which have previously
demonstrated to be associated with decrease in symptoms (98),
may also be useful for improving functional outcome in psychosis
(67). Metacognition Reflection and Insight Therapy (MERIT)
is specifically aimed at improving metacognitive ability (99).
However, De Jong et al. (100) recently demonstrated, in a
trial of MERIT for individuals with schizophrenia, evidence of
improved metacognitive ability but not functioning. The lack of
improvement in functioning may be due to shorter follow-up
period or may be accounted for by other factors, e.g., functional
capacity or negative symptoms [see (32, 101)]. Therefore, new
interventions, such as cognitive remediation, should continue
to aim to improve both cognitions and real-life skills and
additionally consider training metacognitive ability [e.g., Cella
et al. (102)].
Limitations and Future Studies
Firstly, there was a low follow-up rate. This may be due to
the long period between the two assessment points and during
this time the participant either moved out of area, lost contact
with study team, or could not remember the first study due to
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FIGURE 2 | Bar graph to demonstrate differences in mean follow-up time-use scores (including CI for current data) for those with high or low metacognitive ability at
baseline compared to previous data from Hodgekins et al. (15).
length of time or being unwell during the first assessment. A
consequence of this low follow-up rate was the small sample
size, which limited power and it was not possible to fully explore
the role of negative symptoms, alongside metacognitive ability.
Future studies using a large sample can confirm the results whilst
(i) controlling for all symptoms and (i) exploring the interaction
between symptoms and metacognitive ability. Follow-up rate
could be improved by continuity of the researcher across research
visits, regular contact to maintain rapport, and updating of
contact information.
In terms of measurement, this study used the PANSS to
assess negative symptoms which may not align with current
negative symptoms conceptualizations [see (103)], e.g., negative
symptoms are a distinct therapeutic area of interest and negative
symptoms are independent from depression, medication side
effects and neurocognition. Future studies could assess negative
symptoms using Clinical Assessment Interview for Negative
Symptoms (CAINS) (104) or Brief Negative Symptom Scale
(BNSS) (105) and could assess, or control for, other psychotic
symptoms which could be deemed as secondary negative
symptoms (40).
This sample was on average lower on symptoms of psychosis
at baseline and follow-up (106) compared to other FEP samples
(69, 107), which may explain the lack of change in positive
symptoms. Whilst this study demonstrated that metacognitive
ability, measured using Metacognitive Assessment Interview,
had a large predictive role on functioning, other measures of
metacognition, e.g., metacognitive experience (online appraisal)
has been associated with social, real-world and work functioning
(108–110). Future studies should aim to replicate this follow-
up study with addition of other metacognitive measures. Finally,
age was used as a covariate within the main analyses assessing
predictors of outcome, as it was associated with functional
outcome at follow-up. Age was recently demonstrated as a
positive predictor of structured activity in At Risk Mental State
(ARMS) group (111) and it may be suggested that age is a
proxy for illness severity as those who have an earlier psychosis
onset may have more difficulties in functioning later on (112).
However, age of onset is difficult to measure and research
suggests that premorbid IQ accounts for this difference (113).
Analyses without age as a covariate demonstrated no difference
in the results.
CONCLUSION
The present 3-year follow-up study was able to demonstrate
that metacognitive ability at baseline significantly predicted
improvement in functioning after 3 years, in FEP. This was
independent of neurocognition, functional capacity, and negative
symptoms. This study highlighted the importance of intervening
early to enhance metacognitive ability over neurocognitive ability
or functional capacity, in order to improve functioning later
on, and to target interventions to improve functioning in
those with poor metacognitive ability in the early stages of
psychosis. Future studies should aim to replicate this within a
larger sample.
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